The U.S. Food and Drug Administration (U.S. FDA) has issued four observations to a formulation manufacturing facility of Aurobindo Pharma subsidiary Eugia Pharma Specialities.
Hosted on MSN
Aurobindo Pharma clarifies on US FDA inspection reports; stock recovers 3% from day's low
Shares of Aurobindo Pharma declined in Wednesday’s trade, dropping over 4 per cent following reports of lapses observed made by the US drug regulator, the US Food and Drug Administration (US FDA). But ...
Eugia III resolution (in the backdrop of fresh observations) and the launch momentum across geographies would be key determinants, say analysts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results